{
    "root": "35923954-c6ec-3d84-e063-6394a90aecf4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20250520",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6950"
        }
    ],
    "indications": {
        "text": "mirtazapine tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "starting dose : 15-mg daily ; may increase maximum recommended dose 45 mg daily . ( 2.1 ) administer orally daily , preferably evening prior sleep . ( 2.1 ) reduce dose gradually discontinuing mirtazapine tablets . ( 2.6 , 5.14 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "mirtazapine tablets supplied : mirtazapine tablets , usp 15 mg available oral pale yellow , oval-shaped , scored , film-coated tablets imprinted \u201c apo \u201d one side \u201c myocardial infarction \u201d bisect \u201c 15 \u201d side . supplied follows : mirtazapine tablets , usp 30 mg available oral light pink , oval-shaped , scored , film-coated tablets imprinted \u201c apo \u201d one side \u201c myocardial infarction \u201d bisect \u201c 30 \u201d side . supplied follows : bottles 500 ndc 42291-952-50 mirtazapine tablets , usp 45 mg available oral white off-white , oval-shaped , unscored , film-coated tablets imprinted \u201c apo \u201d one side \u201c myocardial infarction-45 \u201d side . supplied follows : storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light moisture .",
    "adverseReactions": "mirtazapine tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . known hypersensitivity mirtazapine excipients mirtazapine tablets . severe skin , including reaction eosinophilia systemic symptoms ( dress ) , stevens-johnson syndrome , bullous dermatitis , erythema multiforme toxic epidermal necrolysis reported following mirtazapine tablets [ ( 5.6 ) , ( 6.2 ) ] .",
    "indications_original": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see Clinical Studies (\n  \n   14)]\n \n  .",
    "contraindications_original": "Starting dose: 15-mg once daily; may increase up to maximum recommended dose of 45 mg once daily. ( 2.1 ) Administer orally once daily, preferably in the evening prior to sleep. ( 2.1 ) Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions_original": "Mirtazapine tablets are supplied as:\n                  Mirtazapine Tablets, USP 15 mg are available for oral administration as pale yellow, oval-shaped, scored, film-coated tablets imprinted \u201cAPO\u201d on one side and \u201cMI\u201d bisect \u201c15\u201d on the other side. They are supplied as follows:\n                  \n                  \n                  \n                  \n                  \n                  Mirtazapine Tablets, USP 30 mg are available for oral administration as light pink, oval-shaped, scored, film-coated tablets imprinted \u201cAPO\u201d on one side and \u201cMI\u201d bisect \u201c30\u201d on the other side. They are supplied as follows: \n                  \n                  Bottles of 500 NDC 42291-952-50\n                  \n                  \n                  Mirtazapine Tablets, USP 45 mg are available for oral administration as white to off-white, oval-shaped, unscored, film-coated tablets imprinted \u201cAPO\u201d on one side and \u201cMI-45\u201d on the other side. They are supplied as follows: \n                  \n                  \n                  \n                  \n                  \n                  \n                     Storage\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture.",
    "adverseReactions_original": "Mirtazapine tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see Warnings and Precautions (\n   \n    5.3), Drug Interactions (7)].\n  \n   \n                     \n                     With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets. Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets [\n  \n   see\n                        Warnings and Precautions\n                        (\n   \n    5.6), Adverse Reactions (\n   \n    6.2)]\n  \n   .",
    "drug": [
        {
            "name": "Mirtazapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6950"
        }
    ]
}